PROTECT and NefIgArd two-year proteinuria and eGFR outcomes in adults with IgA nephropathy: matching-adjusted indirect comparison

被引：0
|
作者：
Gong, Wu [1 ]
Diva, Ulysses [1 ]
Bensink, Mark [1 ]
Chai, Xinglei [2 ]
Gao, Sophie [3 ]
Hendry, Bruce [1 ]
Mercer, Alex [4 ]
Zhou, Zheng-Yi [2 ]
机构：
[1] Travere Therapeut Inc, San Diego, CA USA
[2] Anal Grp, Boston, MA USA
[3] Anal Grp, Los Angeles, CA USA
[4] JAMCO Pharm Consulting, Stockholm, Sweden
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2024年 / 39卷
关键词：
D O I：
10.1093/ndt/gfae069.453
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
367
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PROTECT and NefIgArd two-year proteinuria and eGFR outcomes in adults with IgA nephropathy: matching-adjusted indirect comparison
    Gong, Wu
    Diva, Ulysses
    Bensink, Mark
    Chai, Xinglei
    Gao, Sophie
    Hendry, Bruce
    Mercer, Alex
    Zhou, Zheng-Yi
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I744 - I745
  • [2] MATCHING-ADJUSTED INDIRECT COMPARISONS OF EGFR SLOPES IN THE PROTECT STUDY WITH UK RADAR IGA NEPHROPATHY POPULATION AND THE CONTROL ARM OF NEFIGARD
    不详
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2024, 83 (05) : 699 - 699
  • [3] Matching-Adjusted Indirect Comparisons of eGFR slopes in the PROTECT study with UK RaDaR IgA nephropathy population and the control arm of NefIgArd
    Gong, Wu
    Diva, Ulysses
    Bensink, Mark
    Chai, Xinglei
    Xie, Yanwen
    Gao, Sophie
    Hendry, Bruce
    Mercer, Alex
    Zhou, Zheng-Yi
    Rovin, Brad
    Barratt, Jonathan
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I703 - I703
  • [4] Matching-Adjusted Indirect Comparisons of eGFR slopes in the PROTECT study with UK RaDaR IgA nephropathy population and the control arm of NefIgArd
    Gong, Wu
    Diva, Ulysses
    Bensink, Mark
    Chai, Xinglei
    Xie, Yanwen
    Gao, Sophie
    Hendry, Bruce
    Mercer, Alex
    Zhou, Zheng-Yi
    Rovin, Brad
    Barratt, Jonathan
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [5] MATCHING-ADJUSTED INDIRECT COMPARISON OF SPARSENTAN VS DELAYED-RELEASE FORMULATION BUDESONIDE FOR PROTEINURIA REDUCTION IN ADULTS WITH IGA NEPHROPATHY
    Chai, Xinglei
    Bensink, Mark
    Gao, Sophie
    Gong, Wu
    Diva, Ulysses
    Hendry, Bruce
    Mercer, Alex
    Zhou, Jenny
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I395 - I395
  • [6] Two-stage matching-adjusted indirect comparison
    Remiro-Azocar, Antonio
    BMC MEDICAL RESEARCH METHODOLOGY, 2022, 22 (01)
  • [7] Matching-adjusted indirect comparison of eGFR in patients with immunoglobulin A nephropathy treated with Nefecon (TRF budesonide) or sparsentan
    Reich, Heather
    Patel, Mit
    Kopiec, Agnieszka
    Fu, Shuai
    Hummel, Noemi
    Lafayette, Richard
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39
  • [8] Matching-adjusted indirect comparison of eGFR in patients with immunoglobulin A nephropathy treated with Nefecon (TRF budesonide) or sparsentan
    Reich, Heather
    Patel, Mit
    Kopiec, Agnieszka
    Fu, Shuai
    Hummel, Noemi
    Lafayette, Richard
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2024, 39 : I734 - I735
  • [9] Correction: Two-stage matching-adjusted indirect comparison
    Antonio Remiro‑Azócar
    BMC Medical Research Methodology, 22
  • [10] PERFORMANCE COMPARISON OF UNANCHORED MATCHING-ADJUSTED INDIRECT COMPARISON AND NAIVE TREATMENT INDIRECT COMPARISON ON SURVIVAL OUTCOMES: A SIMULATION STUDY
    Liu, Y.
    Liu, J.
    He, X.
    Wu, J.
    VALUE IN HEALTH, 2022, 25 (12) : S366 - S366
12345